Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in PTC Therapeutics, Inc. or BioMarin Pharmaceutical Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how PTC Therapeutics, Inc. and BioMarin Pharmaceutical Inc. compare based on key financial metrics to determine which better meets your investment needs.

About PTC Therapeutics, Inc. and BioMarin Pharmaceutical Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Latest Biotechnology and PTC Therapeutics, Inc., BioMarin Pharmaceutical Inc. Stock News

As of November 26, 2025, PTC Therapeutics, Inc. had a $6.9 billion market capitalization, compared to the Biotechnology median of $217.8 million. PTC Therapeutics, Inc.’s stock is up 90.5% in 2025, up 12.5% in the previous five trading days and up 99.51% in the past year.

Currently, PTC Therapeutics, Inc.’s price-earnings ratio is 9.6. PTC Therapeutics, Inc.’s trailing 12-month revenue is $1.8 billion with a 42.3% net profit margin. Year-over-year quarterly sales growth most recently was 7.2%. Analysts expect adjusted earnings to reach $8.795 per share for the current fiscal year. PTC Therapeutics, Inc. does not currently pay a dividend.

As of November 26, 2025, BioMarin Pharmaceutical Inc. had a $10.7 billion market cap, putting it in the 80th percentile of all stocks. BioMarin Pharmaceutical Inc.’s stock is down 14.9% in 2025, up 6.6% in the previous five trading days and down 13.6% in the past year.

Currently, BioMarin Pharmaceutical Inc.’s price-earnings ratio is 20.7. BioMarin Pharmaceutical Inc.’s trailing 12-month revenue is $3.1 billion with a 16.8% net profit margin. Year-over-year quarterly sales growth most recently was 4.1%. Analysts expect adjusted earnings to reach $3.577 per share for the current fiscal year. BioMarin Pharmaceutical Inc. does not currently pay a dividend.

How We Compare PTC Therapeutics, Inc. and BioMarin Pharmaceutical Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at PTC Therapeutics, Inc. and BioMarin Pharmaceutical Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

PTC Therapeutics, Inc. and BioMarin Pharmaceutical Inc. Growth Grades

Company	Ticker	Growth
PTC Therapeutics, Inc.	PTCT	F
BioMarin Pharmaceutical Inc.	BMRN	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

PTC Therapeutics, Inc. has a Growth Score of 20, which is Very Weak. BioMarin Pharmaceutical Inc. has a Growth Score of 87, which is Very Strong.

The Growth Grade Winner: BioMarin Pharmaceutical Inc.

As you can clearly see from the Growth Grade breakdown above, BioMarin Pharmaceutical Inc. has a more attractive growth grade than PTC Therapeutics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, BioMarin Pharmaceutical Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

PTC Therapeutics, Inc. and BioMarin Pharmaceutical Inc.’s Momentum Grades

Company	Ticker	Momentum
PTC Therapeutics, Inc.	PTCT	A
BioMarin Pharmaceutical Inc.	BMRN	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

PTC Therapeutics, Inc. has a Momentum Score of 94, which is Very Strong. BioMarin Pharmaceutical Inc. has a Momentum Score of 35, which is Weak.

The Momentum Grade Winner: PTC Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, PTC Therapeutics, Inc. is considered to have stronger momentum compared to BioMarin Pharmaceutical Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, PTC Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

PTC Therapeutics, Inc. and BioMarin Pharmaceutical Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
PTC Therapeutics, Inc.	PTCT	B
BioMarin Pharmaceutical Inc.	BMRN	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

PTC Therapeutics, Inc. has a Earnings Estimate Score of 80, which is Positive. BioMarin Pharmaceutical Inc. has a Earnings Estimate Score of 33, which is Negative.

The Earnings Estimate Revisions Grade Winner: PTC Therapeutics, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, PTC Therapeutics, Inc. has a better Earnings Estimate Revisions Grade than BioMarin Pharmaceutical Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, PTC Therapeutics, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other PTC Therapeutics, Inc. and BioMarin Pharmaceutical Inc. Grades

In addition to Estimate Revisions, Growth and Momentum, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether PTC Therapeutics, Inc. and BioMarin Pharmaceutical Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, PTC Therapeutics, Inc. or BioMarin Pharmaceutical Inc. Stock?

Overall, PTC Therapeutics, Inc. stock has a Growth Score of 20, Momentum Score of 94 and Estimate Revisions Score of 80.

BioMarin Pharmaceutical Inc. stock has a Growth Score of 87, Momentum Score of 35 and Estimate Revisions Score of 33.

Comparing PTC Therapeutics, Inc. and BioMarin Pharmaceutical Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.